658.02

0.93% 6.04

Thermo Fisher Scientific Inc (TMO)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Thermo Fisher Scientific Inc stock is traded at $658.02, with a volume of 1.58M. It is up +0.93% in the last 24 hours and up +8.64% over the past month. Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).

Previous Close:

$651.98

Open:

$650

24h Volume:

1.58M

Relative Volume:

0.75

Market Cap:

$243.30B

Revenue:

$45.20B

Net Income/Loss:

$6.87B

P/E Ratio:

36.18

EPS:

18.1888

Net Cash Flow:

$6.75B

1W Performance:

+0.49%

1M Performance:

+8.64%

6M Performance:

+31.48%

1Y Performance:

+23.07%

1-Day Range:

$644.16

$661.94

1-Week Range:

$635.32

$694.33

52-Week Range:

$435.27

$694.33

Thermo Fisher Scientific Inc Stock (TMO) Company Profile

Name

Thermo Fisher Scientific Inc

Sector

Healthcare (1050)

Industry

Diagnostics & Research (44)

Phone

(781) 622-1000

Address

168 THIRD AVENUE, WALTHAM, MA

Employee

125,000

Twitter

@thermofisher

Next Earnings Date

2026-10-21

Latest SEC Filings

TMO's Discussions on Twitter

Compare TMO vs DHR, NTRA, A, IQV

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TMO Thermo Fisher Scientific Inc	658.02	243.30B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	219.81	154.52B	24.78B	3.68B	5.29B	5.1743
NTRA Natera Inc	400.71	57.76B	2.50B	-226.32M	71.51M	-1.6412
A Agilent Technologies Inc	170.54	48.08B	7.23B	1.41B	1.09B	4.979
IQV Iqvia Holdings Inc	259.88	42.78B	16.63B	1.39B	2.12B	8.0674

Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-09-26	Upgrade	UBS	Neutral → Buy
Sep-03-26	Initiated	CLSA	Outperform
Jun-26-26	Resumed	Bernstein	Mkt Perform
Jun-11-26	Initiated	Piper Sandler	Neutral
Jun-03-26	Downgrade	HSBC Securities	Buy → Hold
Jun-02-26	Resumed	Wolfe Research	Outperform
May-15-26	Resumed	RBC Capital Mkts	Sector Perform
Mar-27-26	Initiated	DZ Bank	Buy
Dec-11-25	Upgrade	Citigroup	Neutral → Buy
Dec-09-25	Initiated	Goldman	Buy
Dec-08-25	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight
Dec-02-25	Resumed	Morgan Stanley	Overweight
Dec-01-25	Upgrade	HSBC Securities	Hold → Buy
Sep-11-25	Upgrade	Barclays	Equal Weight → Overweight
Aug-19-25	Initiated	William Blair	Outperform
Jul-24-25	Downgrade	HSBC Securities	Buy → Hold
Jul-11-25	Upgrade	Scotiabank	Sector Perform → Sector Outperform
Jul-09-25	Downgrade	UBS	Buy → Neutral
Jan-10-25	Upgrade	Bernstein	Mkt Perform → Outperform
Dec-23-24	Initiated	Scotiabank	Sector Perform
Oct-14-24	Initiated	Redburn Atlantic	Buy
Oct-01-24	Initiated	Stephens	Overweight
Aug-28-24	Initiated	Wells Fargo	Overweight
Jun-03-24	Resumed	Jefferies	Buy
Mar-18-24	Resumed	Citigroup	Neutral
Jan-24-24	Downgrade	Barclays	Overweight → Equal Weight
Jan-08-24	Downgrade	Bernstein	Outperform → Mkt Perform
Dec-18-23	Initiated	HSBC Securities	Buy
Dec-13-23	Initiated	Wolfe Research	Outperform
Oct-26-23	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Oct-25-23	Upgrade	Wells Fargo	Underweight → Equal Weight
Sep-28-23	Initiated	Bernstein	Outperform
Sep-06-23	Resumed	Citigroup	Buy
Jul-19-23	Initiated	Raymond James	Outperform
Jul-19-23	Reiterated	Robert W. Baird	Outperform
Jul-13-23	Upgrade	Credit Suisse	Neutral → Outperform
Apr-04-23	Reiterated	Barclays	Overweight
Dec-14-22	Initiated	Deutsche Bank	Buy
Dec-07-22	Initiated	RBC Capital Mkts	Outperform
Oct-27-22	Downgrade	The Benchmark Company	Buy → Hold
Aug-25-22	Initiated	Credit Suisse	Neutral
Apr-25-22	Downgrade	Wells Fargo	Equal Weight → Underweight
Jan-26-22	Resumed	Barclays	Overweight
Oct-20-21	Upgrade	Citigroup	Neutral → Buy
Oct-15-21	Resumed	Cowen	Outperform
Aug-05-21	Resumed	Credit Suisse	Outperform
Jul-16-21	Initiated	The Benchmark Company	Buy
Mar-18-21	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight
Mar-03-21	Initiated	Barclays	Overweight
Jan-08-21	Upgrade	Credit Suisse	Neutral → Outperform
Dec-16-20	Downgrade	Citigroup	Buy → Neutral
Dec-02-20	Initiated	Goldman	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight
Sep-30-20	Initiated	Atlantic Equities	Overweight
Sep-14-20	Initiated	Morgan Stanley	Overweight
Aug-20-20	Resumed	JP Morgan	Overweight
Jul-15-20	Upgrade	Cleveland Research	Neutral → Buy
Jul-07-20	Reiterated	Needham	Buy
Apr-23-20	Reiterated	Needham	Buy
Jan-31-20	Reiterated	Needham	Buy
Jan-22-20	Initiated	Credit Suisse	Neutral
Jan-08-20	Initiated	Wells Fargo	Equal Weight
Jan-07-20	Initiated	Citigroup	Buy
Nov-15-19	Initiated	Stifel	Buy
Jul-25-19	Reiterated	Needham	Buy
Jul-16-19	Downgrade	Needham	Strong Buy → Buy
May-30-19	Initiated	Wolfe Research	Outperform
May-23-19	Reiterated	Needham	Strong Buy
Apr-22-19	Reiterated	Needham	Strong Buy
Apr-16-19	Reiterated	BofA/Merrill	Buy

View All

Thermo Fisher Scientific Inc Stock (TMO) Latest News

Oct 09, 2026

Global Decentralized Clinical Trials Market Size, Trends, and Forecast, 2025-2030 | AI, Wearables, and Cloud-Based Platforms Fuel 13.7% CAGR to $18.8 Billion - GlobeNewswire Inc.

Oct 09, 2026

Oct 07, 2026

Is This the Right Time to Add TMO Stock to Your Portfolio? - Zacks Investment Research

Oct 07, 2026

Oct 06, 2026

JPMorgan Adds AmEx, Thermo Fisher and Liberty Energy to October Overweight Picks - BigGo Finance

Oct 06, 2026

Thermo Fisher Scientific stock heads into October 21 results after a 2.27 percent drop - AD HOC NEWS

Oct 06, 2026

Thermo Fisher Scientific (TMO): Strong Q3 Guidance and Broadening Demand Support Multi-Year Outlook - Yahoo Finance

Oct 06, 2026

Barclays Adjusts Thermo Fisher Scientific Price Target to $750 From $650, Maintains Overweight Rating - marketscreener.com

Oct 06, 2026

Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis - GlobeNewswire Inc.

Oct 06, 2026

Preparations begin for Quantum BioPharma's planned Phase 2 multiple sclerosis drug trial - Stock Titan

Oct 06, 2026

Exclusive: Thermo Fisher To Support Quantum Biopharma in Progressive Multiple Sclerosis Drug Trial - Benzinga

Oct 06, 2026

Thermo Fisher Scientific Showcases New Solutions and Expanded Capabilities to Accelerate Drug Development at CPHI Milan 2026 - BioSpace

Oct 06, 2026

Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation - GlobeNewswire Inc.

Oct 06, 2026

Thermo Fisher Scientific Showcases New Solutions and Expanded Capabilities to Accelerate Drug Development at CPHI Milan 2026 - Business Wire

Oct 06, 2026

Zacks Industry Outlook Globus Medical, Intuitive Surgical and Thermo Fisher Scientific - Zacks Investment Research

Oct 06, 2026

Zacks Industry Outlook Globus Medical, Intuitive Surgical and Thermo Fisher Scientific - TradingView

Oct 06, 2026

Oct 05, 2026